Generic Medicine Info
Indications and Dosage
Purulent otorrhoea
Adult: As 26 mg/mL solution: Instill 5 drops onto affected ear(s) bid for 7 days.
Child: As 26 mg/mL solution: Instill 3 drops onto affected ear(s) bid for 7 days.

Susceptible infections
Adult: As 10 mg/mL spray solution: Spray unto affected area(s) 6-8 hourly or as directed.
Special Precautions
Prolonged use. Hepatic impairment. Pregnancy and lactation.
Adverse Reactions
Significant: Hypersensitivity (e.g. rashes, pruritus, and rarely, anaphylaxis). Reddish discolouration of urine and body fluids.
Patient Counseling Information
This drug may cause permanent staining, remove dentures and soft contact lenses during therapy. May produce red discolouration of urine and other body fluids.
Description: Rifamycin suppresses initiation of chain formation for RNA synthesis in susceptible bacteria by binding to the β subunit of DNA-dependent RNA polymerase, thus blocking RNA transcription.
Distribution: Plasma protein binding: Approx 80%.
Excretion: Mainly via faeces; urine (small amount). Elimination half-life: Approx 1 hour.
Chemical Structure

Chemical Structure Image

Source: National Center for Biotechnology Information. PubChem Database. Rifamycin, CID=6324616, https://pubchem.ncbi.nlm.nih.gov/compound/Rifamycin (accessed on Jan. 22, 2020)

Store below 30°C. Protect from light and moisture.
MIMS Class
Ear Anti-Infectives & Antiseptics / Topical Antibiotics
ATC Classification
S02AA12 - rifamycin ; Belongs to the class of antiinfectives used in the treatment of ear infections.
Buckingham R (ed). Rifamycin Sodium. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 07/05/2018.

Disclaimer: This information is independently developed by MIMS based on Rifamycin from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2022 MIMS. All rights reserved. Powered by MIMS.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in